Sanofi, Regeneron flesh out COPD data with Dupixent

Sanofi and Regeneron have built their case for Dupixent as a first biological therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) congress, as they decide whether to file for approval.